Neuraltus Pharmaceuticals, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q11, R - WEST, X - ALS, X - Alzheimer's, X - Lysosomal Storage, X - Multiple Sclerosis, X - Neuro Degenerative, X - Parkinson's, XX - CA

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Apr

2009

Ambrx, Inc.: Series D $10M

Posted in I - Series D, Q - 2Q09, R - WEST, X - Antibody, X - Growth Deficiency, X - Multiple Sclerosis, XX - CA

Ambrx (La Jolla, CA) a clinical-stage protein therapeutic company focused growth deficiency, closed a $10M Series D financing. Participants include Merck Serono, 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences.

Dec

2008

Apitope International, Ltd.: Series A $12.8M

Posted in I - Series A, Q - 4Q08, R - INTERNATIONAL, X - Diagnostic, X - Multiple Sclerosis, X - RA, X - Vaccines

Apitope International (United Kingdome) developer of vaccines and diagnostics for autoimmune and allergic disease, closed a $12.8M Series A financing. Participants include Vesalius Biocapital, Vinnof and the University of Hasslet.

Feb

2008

PeptImmune, Inc.: Series D $8.2M

Posted in I - Series D, Q - 1Q08, R - NORTH EAST, X - Autoimmune, X - Multiple Sclerosis

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical [...]

to top of page...